Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nasdaq

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Feb 14, 2021 11:01am

154 Views

Post# 32564470

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nasdaq

That being said, it would be in a big pharms's best position to make the hostile offer before we hit the Nasdaq and our true value is obtained, a reasonable known deal is better than the one that could be presented.....$4B is a reasonable buyout for me......$100.sh...

quote=Doccole]

Gents! All the pieces are in play! At anytime we can wake up and see a buy out or deal that would send this screaming upward.

I think few pieces will fall before then. I imagine mid summer, but the beauty of this, anything is possible!

lets continue to add some wind in our sail!

[/quote]

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project